TMS Co., Ltd.

TSE:4891 Stock Report

Market Cap: JP¥8.3b

TMS Valuation

Is 4891 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4891 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4891's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4891's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4891?

Key metric: As 4891 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 4891. This is calculated by dividing 4891's market cap by their current book value.
What is 4891's PB Ratio?
PB Ratio2.8x
BookJP¥2.99b
Market CapJP¥8.27b

Price to Book Ratio vs Peers

How does 4891's PB Ratio compare to its peers?

The above table shows the PB ratio for 4891 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.4x
4564 OncoTherapy Science
8.7xn/aJP¥8.7b
177A Kohjin Bio
2.7x25.7%JP¥9.0b
4597 Solasia Pharma K.K
4.9x71.3%JP¥10.9b
4978 ReproCELL
1.2xn/aJP¥10.7b
4891 TMS
2.8xn/aJP¥8.3b

Price-To-Book vs Peers: 4891 is good value based on its Price-To-Book Ratio (2.8x) compared to the peer average (4.4x).

Price to Book Ratio vs Industry

How does 4891's PB Ratio compare vs other companies in the JP Biotechs Industry?

1 CompanyPrice / BookEstimated GrowthMarket Cap
2342 Transgenic Group
0.6xn/aUS$21.40m
No more companies available in this PB range
4891 2.8xIndustry Avg. 3.6xNo. of Companies4PB02.44.87.29.612+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 4891 is good value based on its Price-To-Book Ratio (2.8x) compared to the JP Biotechs industry average (3.6x).

Price to Book Ratio vs Fair Ratio

What is 4891's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4891 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 4891's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,094.50

7D

-2.1%

1Y

-10.9%

Tsumura

JP¥368.9b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,858.00

7D

1.2%

1Y

76.3%

Daito PharmaceuticalLtd

JP¥32.8b

Manufactures and sells pharmaceutical products worldwide.

4577

JP¥2,147.00

7D

1.8%

1Y

8.8%